The European Commission’s proposal for an EU wide compulsory licensing mechanism
In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...
Updated TRIPS Flexibilities Database
In January 2023, a number of cystic-fibrosis patient organisations asked the governments of Brazil, India, South Africa and Ukraine to invoke compulsory licensing and...
New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...
How not to solve a crisis: The European Commission’s Plan for Transferable Data Exclusivity...
Drug-resistant infections, sometimes called “superbugs,” killed an estimated 1.27 million people in 2019, a number set to rise to 50 million by 2050. It is...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Wrapping up 2022 with some noteworthy medicines, law and policy events
Welcome to our annual, highly biased, overview of noteworthy events in the field of medicines law and policy.
Also in 2022, Covid-19 remained a central...
The Waiver that Wasn’t: Is the pharma lobby responsible?
Systemic lobbying pressure from pharmaceutical companies – allegedly attached to threats to withdraw investments – may have been responsible for the watering down of...
TRIPS, technology transfer and access to pandemic countermeasures: What the WHO Pandemic Treaty must...
The scrambling for access to Covid-19 vaccines by developing countries has reignited the debate on the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS)...